What happened, in summary

A 63-year-old woman was diagnosed with Stage III left lower-lobe lung adenocarcinoma. The tumor carried an EGFR mutation, was ALK-negative, and had PD-L1 expression below 1%. She was not treated surgically and started erlotinib. After about a month, treatment was combined with a dendritic-cell vaccine using WT1 and MUC1 tumor antigens. She ultimately received 15 vaccine doses while continuing erlotinib. Imaging showed the tumor shrinking substantially, including a reduction to about one-third of its original size after several months. By day 321 after treatment began, CT scans no longer detected lung cancer. The disappearance of the tumor remained confirmed for at least 587 days, with no evidence of recurrence or metastasis during that period. The vaccine was well tolerated without documented treatment-related adverse events.